FIELD: chemistry.
SUBSTANCE: present invention relates to compositions containing barrel bark extract Pinus pinaster, papain and leaf extract Aloe Vera. Disclosed is a composition for treating or preventing high blood glucose, containing a barrel bark extract Pinus pinaster, papain and leaf extract Aloe Vera, in which barrel bark extract Pinus pinaster is present in concentration from 2 mg/ml to 10 mg/ml, papain is present in concentration from 1 mg/ml to 5 mg/ml, leaf extract Aloe Vera is present in concentration from 0.5 mg/ml to 4 mg/ml. Also disclosed are: a composition for preventing or delaying the onset of developing type 2 diabetes mellitus (DM2T); a composition for treating or preventing prediabetes; a composition for reducing inflammation; a composition for reducing cytokine-induced inflammation; a composition for reducing the oxidative stress reaction; composition for treating or preventing a disease characterized by high levels of cytokine-induced inflammation; composition for treating or preventing a disease characterized by high levels of oxidative stress; composition for reducing one or more side effects of the drug for treating diabetes selected from a group consisting of metformin, sulphonyl urea, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin therapy; composition for treating or preventing dysfunction associated with excess blood glucose; composition for blood cholesterol reduction; composition for treating an autoimmune disease; aqueous composition for treating or preventing high blood glucose; aqueous composition for preventing or delaying the onset of developing type 2 diabetes mellitus (DM2T); aqueous composition for treating or preventing prediabetes; aqueous composition for reducing inflammation; aqueous composition for reducing cytokine-induced inflammation; aqueous composition for reducing oxidative stress reaction; aqueous composition for treating or preventing a disease characterized by high levels of cytokine-induced inflammations; aqueous composition for treating or preventing a disease characterized by elevated levels of oxidative stress; aqueous composition for reducing one or more side effects of the drug for treating diabetes selected from a group consisting of metformin, sulphonyl urea, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and insulin therapy; aqueous composition for treating or preventing the dysfunction associated with excess blood glucose; aqueous composition for blood cholesterol reduction; aqueous composition for treating an autoimmune disease; method of preparing an aqueous composition.
EFFECT: compositions described above have a synergetic effect on the above diseases.
49 cl, 8 dwg, 7 tbl, 16 ex
